Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606134 · ClinicalTrials.gov registry record · NA
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
A NA study of Acne Scars - Mixed Atrophic and Hypertrophic, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04606134 is a NA study of Acne Scars - Mixed Atrophic and Hypertrophic that has completed, run by University of Rochester. The registered enrollment target is 10 participants, below the 110-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04606134, a NA study of Acne Scars - Mixed Atrophic and Hypertrophic, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.
Conditions Studied
Interventions
- DEVICE Hybrid fractional laser
- OTHER Alastin Regenerating Skin Nectar with TriHex Technology
- OTHER Cetaphil face cream
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2021-06-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04606134
The ClinicalTrials.gov registry entry for NCT04606134 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 110-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (91% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Scars - Mixed Atrophic and Hypertrophic appearing as the primary indexed condition, and to 3 interventions - of which Hybrid fractional laser is the first listed.
NCT04606134 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04606134 about?
NCT04606134 is a clinical study titled "Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring". To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturize...
What is the current status of trial NCT04606134?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2020-02-13. Estimated completion is 2021-06-18.
What conditions does trial NCT04606134 study?
This clinical trial studies the following conditions: Acne Scars - Mixed Atrophic and Hypertrophic.
What interventions are being tested in trial NCT04606134?
The interventions under investigation include: Hybrid fractional laser (DEVICE), Alastin Regenerating Skin Nectar with TriHex Technology (OTHER), Cetaphil face cream (OTHER).
Who is sponsoring clinical trial NCT04606134?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04606134 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Scars - Mixed Atrophic and Hypertrophic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color
RECRUITING · NA
-
The MIRIA Acne Scar Study
ACTIVE NOT RECRUITING · NA
-
AV-23-001 AVAVA MIRIA Pilot Study
ACTIVE NOT RECRUITING · NA
-
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars
COMPLETED · NA
-
Functional Usability and Feasibility Testing of the Profound Matrix™ System
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.